DexCom Statistics
Total Valuation
DexCom has a market cap or net worth of $44.41 billion. The enterprise value is $44.04 billion.
Market Cap | 44.41B |
Enterprise Value | 44.04B |
Important Dates
The next confirmed earnings date is Thursday, July 25, 2024, after market close.
Earnings Date | Jul 25, 2024 |
Ex-Dividend Date | n/a |
Share Statistics
DexCom has 397.68 million shares outstanding. The number of shares has decreased by -0.43% in one year.
Shares Outstanding | 397.68M |
Shares Change (YoY) | -0.43% |
Shares Change (QoQ) | -0.10% |
Owned by Insiders (%) | 0.31% |
Owned by Institutions (%) | 97.45% |
Float | 393.86M |
Valuation Ratios
The trailing PE ratio is 72.51 and the forward PE ratio is 59.41. DexCom's PEG ratio is 2.53.
PE Ratio | 72.51 |
Forward PE | 59.41 |
PS Ratio | 11.68 |
Forward PS | 9.65 |
PB Ratio | 19.76 |
P/FCF Ratio | 76.10 |
PEG Ratio | 2.53 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 44.44, with an EV/FCF ratio of 75.48.
EV / Earnings | 68.89 |
EV / Sales | 11.58 |
EV / EBITDA | 44.44 |
EV / EBIT | 55.46 |
EV / FCF | 75.48 |
Financial Position
The company has a current ratio of 2.90, with a Debt / Equity ratio of 1.13.
Current Ratio | 2.90 |
Quick Ratio | 2.43 |
Debt / Equity | 1.13 |
Debt / EBITDA | 2.56 |
Debt / FCF | 4.34 |
Interest Coverage | 50.58 |
Financial Efficiency
Return on equity (ROE) is 29.40% and return on invested capital (ROIC) is 11.20%.
Return on Equity (ROE) | 29.40% |
Return on Assets (ROA) | 9.80% |
Return on Capital (ROIC) | 11.20% |
Revenue Per Employee | $396,021 |
Profits Per Employee | $66,594 |
Employee Count | 9,600 |
Asset Turnover | 0.58 |
Inventory Turnover | 2.96 |
Taxes
In the past 12 months, DexCom has paid $139.10 million in taxes.
Income Tax | 139.10M |
Effective Tax Rate | 17.87% |
Stock Price Statistics
The stock price has decreased by -16.44% in the last 52 weeks. The beta is 1.16, so DexCom's price volatility has been higher than the market average.
Beta (5Y) | 1.16 |
52-Week Price Change | -16.44% |
50-Day Moving Average | 118.56 |
200-Day Moving Average | 117.74 |
Relative Strength Index (RSI) | 43.59 |
Average Volume (20 Days) | 2,748,028 |
Short Selling Information
The latest short interest is 10.31 million, so 2.59% of the outstanding shares have been sold short.
Short Interest | 10.31M |
Short Previous Month | 9.01M |
Short % of Shares Out | 2.59% |
Short % of Float | 2.62% |
Short Ratio (days to cover) | 3.08 |
Income Statement
In the last 12 months, DexCom had revenue of $3.80 billion and earned $639.30 million in profits. Earnings per share was $1.54.
Revenue | 3.80B |
Gross Profit | 2.39B |
Operating Income | 651.60M |
Pretax Income | 778.40M |
Net Income | 639.30M |
EBITDA | 991.00M |
EBIT | 794.10M |
Earnings Per Share (EPS) | $1.54 |
Balance Sheet
The company has $2.90 billion in cash and $2.53 billion in debt, giving a net cash position of $364.50 million or $0.92 per share.
Cash & Cash Equivalents | 2.90B |
Total Debt | 2.53B |
Net Cash | 364.50M |
Net Cash Per Share | $0.92 |
Equity (Book Value) | 2.25B |
Book Value Per Share | 5.65 |
Working Capital | 3.03B |
Cash Flow
In the last 12 months, operating cash flow was $802.30 million and capital expenditures -$218.80 million, giving a free cash flow of $583.50 million.
Operating Cash Flow | 802.30M |
Capital Expenditures | -218.80M |
Free Cash Flow | 583.50M |
FCF Per Share | $1.50 |
Margins
Gross margin is 62.82%, with operating and profit margins of 17.14% and 16.82%.
Gross Margin | 62.82% |
Operating Margin | 17.14% |
Pretax Margin | 20.47% |
Profit Margin | 16.82% |
EBITDA Margin | 26.07% |
EBIT Margin | 20.89% |
FCF Margin | 15.35% |
Dividends & Yields
DexCom does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | 0.43% |
Shareholder Yield | 0.43% |
Earnings Yield | 1.44% |
FCF Yield | 1.31% |
Analyst Forecast
The average price target for DexCom is $139.47, which is 24.91% higher than the current price. The consensus rating is "Strong Buy".
Price Target | $139.47 |
Price Target Difference | 24.91% |
Analyst Consensus | Strong Buy |
Analyst Count | 15 |
Revenue Growth Forecast (5Y) | 17.38% |
EPS Growth Forecast (5Y) | 25.37% |
Stock Splits
The last stock split was on June 13, 2022. It was a forward split with a ratio of 4:1.
Last Split Date | Jun 13, 2022 |
Split Type | Forward |
Split Ratio | 4:1 |
Scores
DexCom has an Altman Z-Score of 8.09 and a Piotroski F-Score of 6.
Altman Z-Score | 8.09 |
Piotroski F-Score | 6 |